

Activated thiol Sepharose-based proteomic approach to globally quantify protein oxidation

Yang Xu^{1,2,3} and Benjamin G Neel^{1,2,3*}

¹Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada M5G 1L7; ²Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada M5G 1L7; ³Laura and Isaac Perlmutter Cancer Center, New York University Langone Medical Center, New York, New York 10016, USA.

Running title: ATS-based proteomics for detecting protein oxidation

*To whom correspondence should be addressed: Benjamin G. Neel: Laura and Isaac Perlmutter Cancer Center, New York University Langone Medical Center, New York, New York 10016, USA; Benjamin.Neel@nyulangone.org; Tel. (212) 263-3019.

Key words: protein oxidation, redox regulation, PKM2, HLRCC, ATSP, proteomics

Financial support: This work was supported by R01CA49152 (BGN) and the Princess Margaret Cancer Foundation.

Conflicts of interest: BGN is a co-founder, has equity in, and receives consulting funds from, Northern Biologics, and is a co-founder, chair of the Scientific Advisory Board, has equity in, and receives consulting funds from, Navire Pharmaceuticals. A member of his immediate family has equity in Array Pharmaceuticals and Mirati Pharmaceuticals, Inc.

The abbreviations used are: ATS, activated thiol Sepharose; ATSP, ATS-based proteomic approach; ROS, reactive oxygen species; HLRCC, hereditary leiomyomatosis and renal cell carcinoma; FH, fumarate hydratase; PKM2, pyruvate kinase M2 isoform; DMF, dimethyl fumarate; PTM, post translational modification; PTP, protein tyrosine phosphatase; MS, mass spectrometry; ICAT, isotope-coded affinity tag; TKT, transketolase; RT, room temperature; IB, immunoblot; WCL, whole cell lysate; NEM, *N*-ethylmaleimide; DTT, dithiothreitol; TCEP, tris(2-carboxyethyl)phosphine; IAM, iodoacetamide; WT, wild-type; PPP, pentose phosphate pathway; SSP, serine synthesis pathway; RyR1, skeletal-type ryanodine receptor.

Abstract

Reactive oxygen species (ROS) can act as second messengers for various signaling pathways, and abnormal oxidation contributes to multiple diseases, including cancer. Detecting and quantifying protein oxidation is crucial for a detailed understanding of redox signaling. We developed an Activated Thiol Sepharose (ATS)-based proteomic approach (ATSP) to globally quantify protein oxidation. ATSP can enrich for H₂O₂-sensitive thiol peptides, which are more likely to contain reactive cysteines involved in redox signaling. We applied our approach to analyze hereditary leiomyomatosis and renal cell carcinoma (HLRCC), a type of kidney cancer that harbors *fumarate hydratase* (*FH*)-inactivating mutations and has elevated ROS levels. Multiple proteins were oxidized in FH-deficient cells, including many metabolic proteins, such as the M2 isoform of pyruvate kinase (PKM2). Treatment of HLRCC cells with dimethyl fumarate (DMF) or PKM2 activators alter PKM2 oxidation levels. This newly developed redox proteomics method can globally detect oxidation of reactive cysteines and can be employed to analyze multiple physiological and pathological conditions.

Introduction

Over the past two decades, increasing evidence has revealed that oxidation of cysteinyl residues is an important post translational modification (PTM) that can regulate enzymatic activity, protein localization, and/or protein-protein interactions (1-3). However, compared with other PTMs, protein oxidation is understudied, at least in part because of technical difficulties in detecting oxidation events (4), such as the instability of some protein oxidation states, post-lysis oxidation from ambient oxidants (mainly O₂), signal attenuation from surrounding antioxidants, and low signal to noise ratio due to the transience of protein oxidation during signal transduction.

Multiple techniques attempt to overcome these difficulties. Some were designed to specifically detect oxidation of protein tyrosine phosphatases (PTPs), which are particularly sensitive to oxidation. The modified in-gel phosphatase assay was the first to detect oxidation of multiple PTPs simultaneously (5,6). Subsequently, our group utilized a specific antibody against the most highly oxidized state of classical PTPs to develop a mass spectrometry (MS)-based approach to globally detect their oxidation (7,8). However, many other types of protein can be oxidized, and in several cases, such oxidation has important physiological and pathological consequences (9-12). More general redox techniques have been developed to globally detect protein oxidation, such as the isotope-coded affinity tag (ICAT) method (13), the modified cysteinyl-labeling assay (14,15), and dimedone/dimedone antibody-based approaches (16-19). Nevertheless, each has certain technical limitations. For example, the ICAT method measures decreases in oxidation signal after cellular stimulation, resulting in an intrinsically low signal to noise ratio (4). Although dimedone analogs directly label oxidized cysteines, they mainly react with sulfenic acids (S-OH), which are only one of the oxidation states of cysteine. Because the sulfenic acid state is usually labile and rearranges rapidly to a sulfenylamide (S-N) or disulfide (S-S) (20-22), dimedone/dimedone antibody-based approaches might miss important oxidation events, especially in cells under chronic oxidative stress, an important feature of many pathologies.

Activated Thiol Sepharose (ATS), which contains a dipyridyl disulfide group that can bind to free thiol-containing proteins (23), is another promising redox probe. The disulfide bond formed between ATS and free thiols is both strong and reversible, enabling harsh purification conditions, followed by easy, quantitative elution for MS analysis. Several groups have used ATS to assess cysteine oxidation or other cysteine modifications inside cells (24-27). Those studies all featured a protein denaturation step before ATS labelling, which disrupts the local environment of the reactive cysteines (involved in redox signaling), rendering them indistinguishable from structural cysteines (not involved in redox signaling).

We developed an ATS-based proteomic approach (ATSP) that preserves, and thus enriches for, reactive cysteines. We applied ATSP to *fumarate hydratase (FH)*-mutated HLRCC cell lines and identified multiple proteins, especially metabolic proteins, that were oxidized in these cells, including PKM2 and transketolase (TKT). PKM2 oxidation was confirmed by immunoblot (IB) and could be modulated by treating cells with DMF or PKM2 activators. We conclude that ATSP has great potential for detecting reactive cysteine oxidation in redox signaling.

Results

Development of ATSP to detect protein oxidation

Reactive cysteines usually have lower pK_a s than typical cysteines ($pK_a \sim 8.5$). Consequently, reactive cysteines exist as thiolate anions (S^-) at physiological pH, rendering them more chemically reactive to substrates, ROS, and/or other chemicals (28). For ATSP, cells are lysed in de-gassed, non-denaturing lysis buffer containing *N*-ethylmaleimide (NEM); under these conditions, reduced (but not oxidized) cysteinyl residues react with the NEM. Oxidized (reactive) cysteinyl residues that have escaped alkylation are then reduced with dithiothreitol (DTT), incubated with ATS resin, placed in sample buffer for immunoblotting, or processed for MS (Fig. 1A and Methods). To enhance the specificity of labeling, the ATS incubation is performed at acidic pH with a limited amount of ATS resin (29,30) (also, see below). For MS analysis, ATS-bound proteins are washed in denaturing wash buffer, subjected to two-step on-resin trypsin digestion, eluted with tris(2-carboxyethyl)phosphine (TCEP), and alkylated by iodoacetamide (IAM). ATSP can be modified to quantify total protein levels (ATSP-Total) by leaving out the initial NEM alkylation step and using a sufficient amount of ATS resin (Fig. 1A and Methods). The minimal amount of ATS resin for ATSP is determined empirically for each cell system. For example, as shown in Fig. 1B, a given amount of Rat1 cell lysate was processed by ATSP-Total, with sequentially increased amounts of ATS resin. As the readout, we used SHP2, which, as a member of PTP superfamily, has a very reactive catalytic cysteinyl residue. The lowest amount of ATS (20 μ L in this case) that can deplete SHP2 from supernatant is used for ATSP (Fig. 1B).

We used ATSP, followed by immunoblotting, to assess protein oxidation in Rat1 cells treated with H_2O_2 (Fig. 1C). Multiple previously reported ROS-sensitive proteins were oxidized upon H_2O_2 treatment, including PTPs (SHP2 and PTEN), kinases (AKT and ERK2), an adaptor protein (GRB2), and a glycolytic enzyme (PKM2). We also processed the same H_2O_2 -treated samples by MS. Approximately 3,300 unique cysteine-containing peptides, comprising $\sim 1,300$ distinct proteins were detected by MS (Table 1A). As expected, ATSP highly enriched for cysteine-containing peptides, with more than 98% of all the peptides identified by MS containing a thiol group (Table 1A). In addition, of the $\sim 3,300$ cysteine-containing peptides, $\sim 1,800$ (representing $\sim 1,000$ proteins) showed significantly increased oxidation after H_2O_2 treatment; these proteins are likely to contain low pK_a reactive cysteines (Supporting information).

Metabolic proteins were highly oxidized in FH-deficient HLRCC cells

HLRCC is an inherited kidney cancer syndrome, associated with inactivating mutations in *fumarate hydratase* (FH), which encodes a TCA cycle enzyme (31). FH loss-of-function leads to accumulation of fumarate, resulting in increased ROS levels (32,33). To assess protein oxidation in HLRCC cells, we applied ATSP to the patient-derived HLRCC cell line UOK262 (FH-deficient), compared with cells in which wild-type FH had been re-introduced (UOK262 FH-WT) (34). Similar to the results seen in H_2O_2 -treated Rat1 cells, $\sim 96\%$ of the MS-recovered peptides from UOK262 cells contained cysteinyl residues (Table 1B). Furthermore, multiple proteins were highly oxidized in FH-deficient cells, including many metabolic enzymes (Fig. 2A), antioxidant proteins (Fig. 2B), and various other proteins, such as those involved in the cytoskeleton, translation and chaperones (Fig. 2C). Among the oxidized metabolic enzymes, multiple cysteines on PKM2 (from the glycolysis pathway), TKT (from the pentose phosphate pathway/PPP), and PSAT1 (from serine synthesis pathway/SSP) had the highest oxidation levels in FH-deficient cells (Fig. 2A).

We used ATSP-IB to validate some of the ATSP-MS results. As predicted by ATSP-MS, PKM2 and TKT were oxidized in FH-deficient, compared with FH-WT, cells (Fig. 3A). The total amount of G6PD and PHGDH, which are involved in the PPP and SSP, respectively, were increased significantly in FH-deficient

cells. By contrast, TKT and PKM2 showed only a little or no increase in expression in FH-deficient cells (Fig. 3A). Similar results were obtained by using another HLRCC patient-derived cell line, UOK268, again comparing FH-deficient cells with FH-WT cells (Fig. 3B). To assess the stoichiometry of PKM2 oxidation, we compared the amount of oxidized PKM2 (using ATSP) with the total amount of PKM2 (using ATSP-Total). On average ~20-30% of PKM2 was oxidized in UOK262 FH-deficient cells (Fig. 3C).

DMF and PKM2 activators can modulate PKM2 oxidation

To test whether PKM2 oxidation is related to intracellular accumulation of fumarate, we treated UOK262 FH-WT cells with dimethyl fumarate (DMF), a cell-permeable fumarate analog. Long-term DMF treatment of FH-WT cells induced PKM2 oxidation and G6PD and PHGDH upregulation to levels similar to those in FH-deficient cells, indicating that the observed protein oxidation and/or overexpression is likely to be the direct consequence of accumulation of fumarate in FH-deficient cells (Fig. 4A).

Oxidation of PKM2 on C358 has been reported in diamide-treated lung cancer cell lines; moreover, C358 oxidation inhibits tetramer formation and impairs its glycolytic activity (35). Pre-treatment with PKM2 activators, which can promote tetramer formation, can protect reduced PKM2 from diamide-induced oxidation (35). At least seven different cysteine sites on PKM2 were oxidized in HLRCC cells, including C358 (Fig. 2A), so we asked whether different PKM2 activators they can reverse PKM2 oxidation. After a 7-day incubation, two out three PKM2 activators, TEPP46 and Activator III, significantly reduced PKM2 oxidation in UOK262 cells, and both PKM2 activators reduced PKM2 oxidation levels in FH-deficient cells to that seen in FH-WT cells (Fig. 4B). These findings suggest that most oxidized cysteine sites on PKM2 are directly or indirectly involved in PKM2 tetramer formation. Although it took TEPP46 1-2 days to reduce PKM2 in FH-deficient cells, Activator III can reverse PKM2 oxidation within 1-hour of treatment (Fig. 4C), indicating that the redox state of PKM2 is quite dynamic.

Finally, we asked whether preventing/reversing PKM2 oxidation by activator treatment would affect cell viability. Both PKM2 activators had only mild differential growth inhibitory effects on FH-deficient, compared with FH-WT, cells, and this effect was only seen after long term PKM2 activator treatment (Fig. 4D). These results indicate that PKM2 oxidation plays a minor role in cell proliferation of FH-deficient cell, at least under these in vitro conditions.

Discussion

Redox signaling is involved in a variety of signaling pathways and diseases, and understanding its roles requires sensitive and specific techniques to detect oxidized proteins. We developed ATSP to globally monitor and quantify oxidation of functional thiol-containing proteins. Because reactive cysteines are only a very small subset of all cysteinyl residues and lack canonical consensus sequence motifs, it is quite difficult to directly identify them and study their regulation (30). ATSP capitalizes on the low-pK_a of such cysteines (36,37) by: 1) lysing cells in non-denaturing conditions to preserve the structures that confer the low pK_as of these reactive cysteines; 2) use relatively acidic labeling buffer to reduce the labeling of non-reactive cysteines (5,29); 3) minimize the concentration of redox probes to label reactive cysteines, whose labeling is less sensitive to the redox probe concentrations than that of non-reactive cysteines (30). In order to get the “limited amount of ATS” for ATSP, we applied ATSP-Total and used SHP2 as a readout. This “limit the amount of ATS” is likely to be adequate for most reactive cysteines because SHP2 depletion was performed on the “total protein” samples while we use it to label the oxidized proteins (typically < 10% of total protein).

We applied ATSP to H₂O₂-treated Rat1 cells and found more than half of all the detected peptides showed significant increase in oxidation. Because H₂O₂ is a relatively mild ROS and mainly reactive cysteines are ROS-sensitive under low to mild oxidative stresses, ATSP can enrich and specifically characterize the redox states of functional reactive cysteines. By applying ATSP to *FH* mutated HLRCC cell lines, we found multiple metabolic proteins were highly oxidized, including at least 7

cysteine sites on PKM2. Although only C358 has been reported to regulate PKM2 tetramer formation, other cysteine sites might be also directly or indirectly involved in tetramer formation because PKM2 activators can fully reverse PKM2 oxidation. Similar results have been reported for skeletal-type ryanodine receptor (RyR1). Although RyR1-C3635 is selectively nitrosylated, 6 additional cysteines on RyR1 may also contribute to the redox regulation of the channel (38,39). In addition, PKM2 plays important roles in multiple cancers (40), and PKM2 oxidation has been implicated to protect lung cancer cells from oxidative stresses (35). Perhaps surprisingly, then, treatment with either of two PKM2 activators had little differential effect on the proliferation of FH-deficient, compared with FH-WT, HLRCC cells. These results do not, however, exclude the possibility that PKM2 oxidation plays a more important role in the proliferation and/or survival of such cells under the more challenging environment of a tumor. Further studies are needed to evaluate this possibility, as well as to determine what other pathways rescue the effects of PKM2 reactivation *in vitro*.

One potential drawback of ATSP is that the ATS might not “fit” into all molecules with reactive cysteines. We used ATS-4B in all of the above experiments, but we have also tested another commercially available ATS, ATS-6B. ATS-6B works well when using the ATSP protocol to detect proteins oxidation by IB (data not shown), but the difference between ATS-6B and ATS-4B in terms of MS-detected ATS-bound protein profile warrants future investigation. Furthermore, some ATS-bound proteins can be detected by IB, but not MS. This indicates that additional procedures are needed to increase the sensitivity of MS detection, for example, sample fractionation or using a different protease (some tryptic peptides might not fly well in MS instruments).

To summarize, we developed a novel redox approach, ATSP, to globally detect protein oxidation. ATSP is suitable to detect oxidation of reactive cysteines, which are more likely to be involved in redox signaling. We applied ATSP to HLRCC cells that have high ROS levels, and we found multiple metabolic proteins were oxidized in these cells, including PKM2. Therefore, ATSP has great potential to be applied in other ROS-related physiological and pathological conditions and help to better understand the redox signaling.

Materials and methods

Cell lines and cell culture

Rat1 cells were kindly provided by Dr. Nicholas Tonks (CSH Laboratory, USA). UOK262 FH-WT, UOK262 FH-deficient, UOK268 FH-WT and UOK268 FH-deficient cells were kindly provided by Dr. W. Marston Linehan (NCI, USA). All the cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM). All media contained 10% FBS (Corning) and 100 Units/ml penicillin/streptomycin (Gibco).

ATS-based proteomic approach

A lysis buffer containing 20 mM Tris-HCl (pH 7.35), 150 mM NaCl, 10% glycerol, 1% NP40 was degassed overnight with vacuum at RT, and then transferred to a hypoxia workstation. NEM (30 mM, Sigma), 0.5 U/μL catalase (Calbiochem), 0.125 U/μL SOD (Sigma) and a protease inhibitor cocktail (2 μg/mL antipain, 2 μg/mL pepstatin A, 20 μg/mL leupeptin, and 20 μg/mL aprotinin) were added to the lysis buffer immediately before using. Within the hypoxia workstation, cells were quickly washed once with degassed PBS, immediately lysed, and incubated for 1 hr at 4°C in the dark with constant rotation. Homogenates were clarified at 10,000× g for 1 min at 4°C. Supernatants were collected, and the buffer was exchanged by gel filtration (GE Healthcare Life Sciences) into the degassed solution (20 mM HEPES [pH 6.5], 100 mM NaCl, 10% glycerol, 0.05% NP40, 0.02 U/μL catalase). Samples were then treated with 1.5 mM DTT and rotated in the dark for 2 hrs at 37°C. Within the hypoxia workstation, lysates were buffer-exchanged again to remove DTT. Activated Thiol Sepharose 4B (GE Healthcare Life Sciences) was added, and the samples were rotated overnight at 4°C in the dark.

For IB, ATS-bound proteins were washed 3× with RIPA buffer, 1× with 8 M urea, and then incubated with 2× Laemmli sample buffer (30 min at 56°C) before resolving on SDS-PAGE. For MS, ATS-bound proteins were first washed 3× with RIPA buffer. ATS-bound proteins were then incubated in a buffer containing 8 M urea and 20 mM IAM (dissolved in 50 mM ammonium bicarbonate [pH 8-8.5]) for 10 min at RT in dark with constant rotation (repeat once). After alkylation, ATS-bound proteins were washed with 50 mM ammonium bicarbonate (pH 8-8.5) (4×), and then digested with 1 µg of trypsin (Thermo Scientific) for 30 min at 37°C with constant rotation. The supernatant after first trypsin digestion was discarded. ATS-bound proteins/peptides were washed once with 50 mM ammonium bicarbonate, and again digested with 1 µg of trypsin overnight at 37°C with constant rotation. The next day, ATS-bound peptides were washed with 50 mM ammonium bicarbonate (3×) and eluted with 1 mM TCEP (Thermo Scientific) for 30 min at 37°C with constant rotation. The eluates were then alkylated with 10 mM IAM (30 min at RT in the dark). The elution/alkylation procedure was repeated one more time, and the two eluates were combined, acidified with trifluoroacetic acid (final pH ~2), purified using StageTips and analyzed by MS.

Immunoblotting

Whole cell lysate (WCL; 10-50 µg), ATS-bound proteins and/or supernatant were resolved by SDS-PAGE and analyzed by immunoblotting. Antibodies included: anti-PGK1/2, anti-FH, and anti-ERK2 antibodies from Santa Cruz Biotechnology; anti-GAPDH antibody from EMD Millipore; anti-HIF1α antibody from BD Transduction Laboratories; anti-PGM1 and anti-TKT antibodies from Abcam; anti-PHGDH, anti-G6PD, anti-PKM2 antibodies from Cell Signaling Technology.

LC-MS/MS

The digested sample was loaded onto an Acclaim PepMap trap column in line with an EASY-Spray PepMap analytical column by using the auto sampler of either the EASY-nLC 1000 or EASY-nLC 1200 HPLC with solvent A, consisting of 2% acetonitrile in 0.5% acetic acid, and solvent B, consisting of 80% acetonitrile in 0.5% acetic acid. Peptides were gradient-eluted into either the Orbitrap Elite or Orbitrap Fusion Lumos Mass Spectrometer. MS1 scans were acquired in the Orbitrap and MS2 scans in the ion trap using a data-dependent acquisition scheme. All acquired MS2 spectra were searched against the UniProt reference proteome database using Sequest within Proteome Discoverer. The search parameters were as follows: precursor mass tolerance ± 10 ppm, fragment mass tolerance ± 0.4 Da, trypsin cleavage with 2 missed cleavages allowed, variable modification of oxidation of methionine, carbamidomethyl and N-ethylmaleimide modification of cysteine, and deamidation of glutamine and asparagine. Label-free quantification was obtained by using Skyline (MacCoss Lab Software; version 4.1.0.11796).

Statistical analysis

Data are presented as the mean ± SEM. Statistical significance was determined using unpaired Student's t-test. Statistical analyses were performed using Graph-Pad Prism 7, with p < 0.05 considered significant.

Acknowledgments

We thank Dr. Nicholas Tonks (CSH Laboratory) for providing Rat1 cells, Dr. W. Marston Linehan (NCI) for providing HLRCC cells, and Dr. Beatrix Ueberheide and Mr. Joshua Andrade (PCC Proteomics Shared Resource) for their help with MS. This work was supported by R01CA49152 (BGN) and the Princess Margaret Cancer Foundation.

Figure/Table Legends

Figure 1. Development of ATSP to detect protein oxidation. A, schematic of ATSP. To detect protein oxidation (ATSP), reduced cysteinyl residues are sequestered by NEM, while the oxidized cysteinyl residues are reduced by DTT before addition of ATS. ATS-bound proteins are subjected to sequential on-resin trypsin digestion, eluted with TCEP, alkylated by IAM, and analyzed by MS. For detection of total proteins (ATSP-Total), all procedures are the same except for the initial alkylation step. B, determination of the amount of ATS resin used for ATSP. Rat1 cells were processed by ATSP-Total, and whole cell lysate (WCL), ATS-bound proteins (pull down, PD), and the supernatant were immunoblotted for SHP2. C, oxidized proteins detected by ATSP. Rat1 cells were treated with 1 mM H₂O₂ (4 min) or left untreated. After processing for ATSP, WCL and the ATS-bound proteins were analyzed by IB.

Figure 2. Protein oxidation in FH-deficient HLRCC cells, detected by ATSP-MS. UOK262 (FH-WT or FH-deficient) cells were processed for ATSP. Metabolic proteins are shown in (A), antioxidant proteins are shown in (B), and other proteins are shown in (C). Data were analyzed by label-free quantification of peptides from each identified protein (n=2-3). H₂O₂, 1 mM for 4 min.

Figure 3. PKM2 is oxidized in FH-deficient cells. A and B, UOK262 (A) and UOK268 (B) (FH-WT and FH-deficient) cells were processed for ATSP. WCL and ATS-bound proteins were analyzed by immunoblotting with the indicated antibodies. The relative amounts of PKM2 and TKT oxidation are quantified below. Data represent mean ± SEM (n=6; *p<0.05, **p<0.01, ***p<0.001; unpaired two-tailed t-test). C, UOK262 (FH-WT and FH-deficient) cells were processed for ATSP or ATSP-Total. WCL and ATS-bound proteins were analyzed by immunoblotting with the indicated antibodies.

Figure 4. DMF and PKM2 activators can modulate PKM2 oxidation. A, UOK262 cells were treated with DMF (100 μM, 7 days) or H₂O₂ (1 mM, 4 min) and processed for ATSP. WCL and ATS-bound proteins were analyzed by immunoblotting with indicated antibodies. B, UOK262 cells were treated with various PKM2 activators (DASA58, 20 μM for 7 days; TEPP46, 20 μM for 7 days; Activator III, 8 μM for 7 days), and processed for ATSP. WCL and ATS-bound proteins were analyzed by immunoblotting with anti-PKM2 antibody. C, FH-deficient UOK262 cells were treated with PKM2 activators (20 μM TEPP46 or 8 μM Activator III) for the indicated time points and processed for ATSP. WCL and ATS-bound proteins were analyzed by immunoblotting with anti-PKM2 antibody. D, UOK262 (FH-WT and FH-deficient) cells were treated with PKM2 activators or DMSO control for the indicated time points. The relative number of viable cells was counted after drug treatments. Data represent mean ± SEM. (n=3; *p<0.05, **p<0.01, ***p<0.001; unpaired two-tailed t test).

Table 1. Total number of peptides and number of IAM-modified peptides by ATSP. A, Rat1 cells were treated with 1 mM H₂O₂ or left untreated. After processing for ATSP and analyzing with MS, the number of total peptides and the cysteine-containing peptides (IAM-modified) were listed (mean ± SEM; n=3). B, UOK262 FH-WT, FH-deficient, and FH-WT-H₂O₂ (1 mM; 4 min) were processing for ATSP and analyzed by MS. The number of total peptides and the cysteine-containing peptides (IAM-modified) were listed (mean ± SEM; n=3).

References

1. Ostman, A., Frijhoff, J., Sandin, A., and Bohmer, F. D. (2011) Regulation of protein tyrosine phosphatases by reversible oxidation. *J Biochem* **150**, 345-356
2. Dinkova-Kostova, A. T., Holtzclaw, W. D., Cole, R. N., Itoh, K., WakATSPyashi, N., Katoh, Y., Yamamoto, M., and Talalay, P. (2002) Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. *Proc Natl Acad Sci U S A* **99**, 11908-11913
3. Liu, H., Nishitoh, H., Ichijo, H., and Kyriakis, J. M. (2000) Activation of apoptosis signal-regulating kinase 1 (ASK1) by tumor necrosis factor receptor-associated factor 2 requires prior dissociation of the ASK1 inhibitor thioredoxin. *Mol Cell Biol* **20**, 2198-2208
4. Karisch, R., and Neel, B. G. (2013) Methods to monitor classical protein-tyrosine phosphatase oxidation. *FEBS J* **280**, 459-475
5. Meng, T. C., Fukada, T., and Tonks, N. K. (2002) Reversible oxidation and inactivation of protein tyrosine phosphatases in vivo. *Mol Cell* **9**, 387-399
6. Meng, T. C., Buckley, D. A., Galic, S., Tiganis, T., and Tonks, N. K. (2004) Regulation of insulin signaling through reversible oxidation of the protein-tyrosine phosphatases TC45 and PTP1B. *J Biol Chem* **279**, 37716-37725
7. Karisch, R., Fernandez, M., Taylor, P., Virtanen, C., St-Germain, J. R., Jin, L. L., Harris, I. S., Mori, J., Mak, T. W., Senis, Y. A., Ostman, A., Moran, M. F., and Neel, B. G. (2011) Global proteomic assessment of the classical protein-tyrosine phosphatome and "Redoxome". *Cell* **146**, 826-840
8. Xu, Y., Taylor, P., Andrade, J., Ueberheide, B., Shuch, B., Glazer, P. M., Bindra, R. S., Moran, M. F., Linehan, W. M., and Neel, B. G. (2018) Pathological Oxidation of PTPN12 Underlies ABL1 Phosphorylation in Hereditary Leiomyomatosis and Renal Cell Carcinoma. *Cancer Res*
9. Frijhoff, J., Dagnell, M., Godfrey, R., and Ostman, A. (2014) Regulation of protein tyrosine phosphatase oxidation in cell adhesion and migration. *Antioxid Redox Signal* **20**, 1994-2010
10. Guo, Z., Kozlov, S., Lavin, M. F., Person, M. D., and Paull, T. T. (2010) ATM activation by oxidative stress. *Science* **330**, 517-521
11. Ishii, T., Sunami, O., Nakajima, H., Nishio, H., Takeuchi, T., and Hata, F. (1999) Critical role of sulfenic acid formation of thiols in the inactivation of glyceraldehyde-3-phosphate dehydrogenase by nitric oxide. *Biochem Pharmacol* **58**, 133-143
12. Lee, J. G., Baek, K., Soetandyo, N., and Ye, Y. (2013) Reversible inactivation of deubiquitinases by reactive oxygen species in vitro and in cells. *Nat Commun* **4**, 1568
13. Sethuraman, M., McComb, M. E., Huang, H., Huang, S., Heibeck, T., Costello, C. E., and Cohen, R. A. (2004) Isotope-coded affinity tag (ICAT) approach to redox proteomics: identification and quantitation of oxidant-sensitive cysteine thiols in complex protein mixtures. *J Proteome Res* **3**, 1228-1233
14. Boivin, B., Zhang, S., Arbiser, J. L., Zhang, Z. Y., and Tonks, N. K. (2008) A modified cysteinyl-labeling assay reveals reversible oxidation of protein tyrosine phosphatases in angiomyolipoma cells. *Proc Natl Acad Sci U S A* **105**, 9959-9964
15. Boivin, B., Yang, M., and Tonks, N. K. (2010) Targeting the reversibly oxidized protein tyrosine phosphatase superfamily. *Sci Signal* **3**, pl2
16. Wani, R., Qian, J., Yin, L., Bechtold, E., King, S. B., Poole, L. B., Paek, E., Tsang, A. W., and Furdui, C. M. (2011) Isoform-specific regulation of Akt by PDGF-induced reactive oxygen species. *Proc Natl Acad Sci U S A* **108**, 10550-10555

17. Paulsen, C. E., Truong, T. H., Garcia, F. J., Homann, A., Gupta, V., Leonard, S. E., and Carroll, K. S. (2011) Peroxide-dependent sulfenylation of the EGFR catalytic site enhances kinase activity. *Nat Chem Biol* **8**, 57-64
18. Tsutsumi, R., Harizanova, J., Stockert, R., Schroder, K., Bastiaens, P. I. H., and Neel, B. G. (2017) Assay to visualize specific protein oxidation reveals spatio-temporal regulation of SHP2. *Nat Commun* **8**, 466
19. Garcia, F. J., and Carroll, K. S. (2016) An immunochemical approach to detect oxidized protein tyrosine phosphatases using a selective C-nucleophile tag. *Mol Biosyst* **12**, 1790-1798
20. Claiborne, A., Miller, H., Parsonage, D., and Ross, R. P. (1993) Protein-sulfenic acid stabilization and function in enzyme catalysis and gene regulation. *FASEB J* **7**, 1483-1490
21. Salmeen, A., Andersen, J. N., Myers, M. P., Meng, T. C., Hinks, J. A., Tonks, N. K., and Barford, D. (2003) Redox regulation of protein tyrosine phosphatase 1B involves a sulphenyl-amide intermediate. *Nature* **423**, 769-773
22. Lee, S. R., Yang, K. S., Kwon, J., Lee, C., Jeong, W., and Rhee, S. G. (2002) Reversible inactivation of the tumor suppressor PTEN by H₂O₂. *J Biol Chem* **277**, 20336-20342
23. Templeton, D. J., Aye, M. S., Rady, J., Xu, F., and Cross, J. V. (2010) Purification of reversibly oxidized proteins (PROP) reveals a redox switch controlling p38 MAP kinase activity. *PLoS One* **5**, e15012
24. Victor, K. G., Rady, J. M., Cross, J. V., and Templeton, D. J. (2012) Proteomic profile of reversible protein oxidation using PROP, purification of reversibly oxidized proteins. *PLoS One* **7**, e32527
25. Liu, M., Hou, J., Huang, L., Huang, X., Heibeck, T. H., Zhao, R., Pasa-Tolic, L., Smith, R. D., Li, Y., Fu, K., Zhang, Z., Hinrichs, S. H., and Ding, S. J. (2010) Site-specific proteomics approach for study protein S-nitrosylation. *Anal Chem* **82**, 7160-7168
26. Guo, J., Gaffrey, M. J., Su, D., Liu, T., Camp, D. G., 2nd, Smith, R. D., and Qian, W. J. (2014) Resin-assisted enrichment of thiols as a general strategy for proteomic profiling of cysteine-based reversible modifications. *Nat Protoc* **9**, 64-75
27. Forrester, M. T., Hess, D. T., Thompson, J. W., Hultman, R., Moseley, M. A., Stamler, J. S., and Casey, P. J. (2011) Site-specific analysis of protein S-acylation by resin-assisted capture. *J Lipid Res* **52**, 393-398
28. Winterbourn, C. C. (2013) The biological chemistry of hydrogen peroxide. *Methods Enzymol* **528**, 3-25
29. Lee, S. R., Kwon, K. S., Kim, S. R., and Rhee, S. G. (1998) Reversible inactivation of protein-tyrosine phosphatase 1B in A431 cells stimulated with epidermal growth factor. *J Biol Chem* **273**, 15366-15372
30. Weerapana, E., Wang, C., Simon, G. M., Richter, F., Khare, S., Dillon, M. B., Bachovchin, D. A., Mowen, K., Baker, D., and Cravatt, B. F. (2010) . *Nature* **468**, 790-795
31. Tomlinson, I. P., Alam, N. A., Rowan, A. J., Barclay, E., Jaeger, E. E., Kelsell, D., Leigh, I., Gorman, P., Lamlum, H., Rahman, S., Royle, R., Olpin, S., Bevan, S., Barker, K., Hearle, N., Houlston, R. S., Kiuru, M., Lehtonen, R., Karhu, A., Vilkkilä, S., Laiho, P., Eklund, C., Vierimaa, O., Aittomäki, K., Hietala, M., Sistonen, P., Paetau, A., Salovaara, R., Herva, R., Launonen, V., Aaltonen, L. A., and Multiple Leiomyoma, C. (2002) Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. *Nat Genet* **30**, 406-410
32. Sudarshan, S., Sourbier, C., Kong, H. S., Block, K., Valera Romero, V. A., Yang, Y., Galindo, C., Mollapour, M., Scroggins, B., Goode, N., Lee, M. J., Gourlay, C. W., Trepel, J., Linehan, W. M., and Neckers, L. (2009) Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and hypoxia-inducible transcription factor 1α stabilization by glucose-dependent generation of reactive oxygen species. *Mol Cell Biol* **29**, 4080-4090

33. Adam, J., Hatipoglu, E., O'Flaherty, L., Ternette, N., Sahgal, N., Lockstone, H., BATSPn, D., Nye, E., Stamp, G. W., Wolhuter, K., Stevens, M., Fischer, R., Carmeliet, P., Maxwell, P. H., Pugh, C. W., Frizzell, N., Soga, T., Kessler, B. M., El-Bahrawy, M., Ratcliffe, P. J., and Pollard, P. J. (2011) Renal cyst formation in Fh1-deficient mice is independent of the Hif/Phd pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling. *Cancer Cell* **20**, 524-537
34. Yang, Y., Valera, V. A., Padilla-Nash, H. M., Sourbier, C., Vocke, C. D., Vira, M. A., Abu-Asab, M. S., Bratslavsky, G., Tsokos, M., Merino, M. J., Pinto, P. A., Srinivasan, R., Ried, T., Neckers, L., and Linehan, W. M. (2010) UOK 262 cell line, fumarate hydratase deficient (FH-/FH-) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer. *Cancer Genet Cytogenet* **196**, 45-55
35. Anastasiou, D., Poulogiannis, G., Asara, J. M., Boxer, M. B., Jiang, J. K., Shen, M., Bellinger, G., Sasaki, A. T., Locasale, J. W., Auld, D. S., Thomas, C. J., Vander Heiden, M. G., and Cantley, L. C. (2011) Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses. *Science* **334**, 1278-1283
36. Lewis, C. T., Seyer, J. M., and Carlson, G. M. (1989) Cysteine 288: an essential hyperreactive thiol of cytosolic phosphoenolpyruvate carboxykinase (GTP). *J Biol Chem* **264**, 27-33
37. Knowles, J. R. (1976) The intrinsic pKa-values of functional groups in enzymes: improper deductions from the pH-dependence of steady-state parameters. *CRC Crit Rev Biochem* **4**, 165-173
38. Sun, J., Xin, C., Eu, J. P., Stamler, J. S., and Meissner, G. (2001) Cysteine-3635 is responsible for skeletal muscle ryanodine receptor modulation by NO. *Proc Natl Acad Sci U S A* **98**, 11158-11162
39. Voss, A. A., Lango, J., Ernst-Russell, M., Morin, D., and Pessah, I. N. (2004) Identification of hyperreactive cysteines within ryanodine receptor type 1 by mass spectrometry. *J Biol Chem* **279**, 34514-34520
40. Dayton, T. L., Jacks, T., and Vander Heiden, M. G. (2016) PKM2, cancer metabolism, and the road ahead. *EMBO Rep* **17**, 1721-1730

Figure 1




Figure 2




Figure 3




Figure 4




Table 1

A			
	IAM-modified peptides	Total peptides	Percentage of IAM-modified peptides
No treatment	2479 ± 88	2517 ± 90	98.48% ± 0.24%
H ₂ O ₂	3283 ± 189	3340 ± 188	98.27% ± 0.12%

B			
	IAM-modified peptides	Total peptides	Percentage of IAM-modified peptides
FH-WT	3416 ± 165	3535 ± 162	96.64% ± 0.30%
FH-deficient	3380 ± 275	3522 ± 289	95.97% ± 0.38%
H ₂ O ₂	4182 ± 16	4326 ± 25	96.66% ± 0.19%